Kbc Group Nv Exelixis, Inc. Transaction History
Kbc Group Nv
- $33.1 Billion
- Q3 2024
A detailed history of Kbc Group Nv transactions in Exelixis, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 7,182 shares of EXEL stock, worth $248,856. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,182
Previous 7,182
-0.0%
Holding current value
$248,856
Previous $161,000
15.53%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding EXEL
# of Institutions
500Shares Held
244MCall Options Held
2.54MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.16 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$1.02 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$880 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$532 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$397 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.2B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...